PHARMAIDS PHARMACEUTICALS LTD. (PHARMAID)

BSE: ₹27.66
Stock Performance
Corporate Announcements
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015-Providing Corporate Guarantee To Subsidiary

Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Providing corporate guarantee to subsidiary, Adita Bio Sys Private Limited

2026-06-13 10:10:03
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper publication of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026

2026-05-31 10:09:06
2026-05-29 19:31:38
Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended March 31, 2026

The Board of Directors of the Company have approved the Audited Financial Results for the quarter and year ended March 31, 2026 at their meeting held on May 29, 2026.

2026-05-29 19:20:26
2026-05-22 17:55:44
Compliances-Reg.24(A)-Annual Secretarial Compliance

Pursuant to the Regulation 24A of SEBI (LODR) Regulations, 2015, enclosed is the Annual Secretarial Compliance Report for the year ended March 31, 2026.

2026-05-08 17:05:45
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper publication regarding the Special Window open for Re-Lodgement of transfer deeds.

2026-04-24 15:09:54
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (Depositaries and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

2026-04-07 14:22:54
Intimation Under Regulation 30 Of SEBI LODR

Sale of entire shareholding held by Adita Bio Sys Private Limited (material subsidiary of the Company) in Siri Labvivo Diet Private Limited, a step-down subsidiary, resulting in cessation of its subsidiary status w.e.f March 27, 2026.

2026-03-27 21:41:20
Closure of Trading Window

Intimation of Trading Window Closure pursuant to declaration of Audited Financial Results for the quarter and Year ended March 31, 2026.

2026-03-25 17:49:30

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 0.00 0.00 0.02 0.01 0.17 0.83 1.21 0.13 1.12 5.97 0.83 2.69
YOY Revenue Growth % - - - - - - 5721.11% 1792.86% 569.85% 615.29% -31.05% 1929.36%
Other Income 0.37 -0.26 -0.90 0.03 0.00 0.01 0.00 1.01 0.35 0.19 0.06 0.06
Total Income 0.37 -0.26 -0.88 0.04 0.17 0.84 1.21 1.14 1.46 6.16 0.89 2.75
Total Expenses + 1.62 1.03 1.33 2.15 1.94 2.03 3.06 4.92 7.15 11.62 5.13 4.42
Cost of Materials Consumed 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.06 9.29 0.33 0.72
Employee Benefit Expense 0.36 0.47 0.86 0.79 0.74 0.72 0.87 1.09 1.40 1.60 1.55 0.85
Other Expenses 1.25 0.55 0.44 1.02 0.99 0.59 1.01 1.57 3.53 2.43 1.76 0.28
Operating Profit -1.62 -1.03 -1.31 -2.14 -1.78 -1.19 -1.85 -4.79 -6.04 -5.65 -4.30 -1.73
OPM % 0% 0% -6308.7% -30566.4% -1067.7% -142.9% -153.1% -3613.5% -541.5% -94.8% -516.1% -64.4%
Profit Before Tax + -1.21 -1.29 -2.21 -2.11 -1.77 -1.19 -1.85 -3.78 -5.69 -2.33 -4.24 -1.69
Tax Expense 0.09 -0.78 -0.58 0.13 -0.15 -0.18 -0.25 -0.72 -1.33 -0.68 -1.13 -0.38
Tax % - - - - - - - - - - - -
Profit After Tax -1.30 -0.50 -1.63 -2.24 -1.62 -1.01 -1.59 -3.06 -4.36 -1.65 -3.11 -1.31
EPS (Basic) -0.61 -0.24 -0.76 -0.99 -0.46 -0.29 -0.45 -0.86 -1.24 -0.47 -0.88 -0.37

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Revenue from Operations 10.60 2.34 0.03 0.00 3.94 8.55
YOY Revenue Growth % 352.92% 8335.68% - -100% -53.93% -
Other Income 0.66 1.02 0.79 0.00 0.02 0.03
Total Income 11.26 3.36 0.82 0.00 3.95 8.58
Total Expenses + 28.33 11.95 6.91 9.91 3.81 8.49
Cost of Materials Consumed 10.91 0.03 0.00 0.00 0.00 0.00
Employee Benefit Expense 5.40 3.42 1.99 1.13 0.10 0.04
Other Expenses 7.99 4.17 4.39 7.87 0.13 0.24
Operating Profit -17.72 -9.61 -6.88 -9.91 0.13 0.06
OPM % -167.2% -410.4% -24799% 0% 3.2% 0.7%
Profit Before Exceptional -17.06 -8.59 -6.09 -9.91 0.14 0.09
Exceptional Items 3.11 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + -13.95 -8.59 -6.09 -9.91 0.14 0.09
Tax Expense -3.52 -1.31 -1.14 -2.35 0.00 0.00
Tax % - - - - -3.5% -5.5%
Profit After Tax -10.44 -7.28 -4.95 -7.56 0.15 0.09
EPS (Basic) -2.95 -2.06 -2.18 -5.86 0.14 0.09

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
ASSETS
Non-Current Assets + 78.14 106.01 80.24 7.07 8.44 8.26
Property, Plant & Equipment 7.91 24.18 16.55 0.11 0.03 0.04
Capital Work in Progress 5.47 3.51 2.30 2.00 0.45 0.45
Non-Current Investments 52.54 52.61 52.60 0.00 0.00 0.00
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.15 0.00 0.00 0.00 0.00 0.00
Current Assets + 5.82 12.68 4.76 17.48 2.67 0.86
Inventories 0.00 9.77 0.23 0.00 0.89 0.37
Trade Receivables 1.38 0.16 0.00 1.39 1.34 0.28
Cash and Cash Equivalents 0.11 0.47 2.46 12.75 0.41 0.20
Current Investments 0.00 0.00 0.00 3.27 0.00 0.00
LIABILITIES & EQUITY
Total Equity 53.38 63.79 71.06 22.43 8.67 8.53
Equity Share Capital 35.27 35.27 35.27 21.44 10.27 10.27
Other Equity 18.11 28.52 35.79 0.98 -1.60 -1.74
Non-Current Liabilities 14.94 39.67 12.84 0.00 0.00 0.00
Current Liabilities 15.64 15.23 1.10 2.13 2.44 0.59
Total Liabilities 30.58 54.90 13.94 2.13 2.44 0.59

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Cash from Operating Activities -3.53 -7.72 -3.44 -4.01 -0.26 0.41
Cash from Investing Activities 24.53 -18.90 -72.51 -4.94 0.47 -0.23
Cash from Financing Activities -21.36 24.64 65.66 21.31 0.00 0.00
Net Increase/Decrease in Cash -0.36 -1.99 -10.29 12.35 0.21 0.18